HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies
- Frange, Pierre
- Assoumou, Pierre
- Descamps, Diane
- Chéret, Antoine
- Goujard, Cécile
- Tran, Laurent
- Gousset, Marine
- Avettand-Fenoël, Véronique
- Bocket, Laurence
- Tran, Samira
- Guinard, Jérôme
- Morand-Joubert, Pierre
- Nicot, Florence
- Plantier, Jean-Christophe
- Rogez, Sylvie
- Wirden, Pierre
- Rouzioux, Christine
- Meyer, Laurence
- Chaix, Marie-Laure
- Abel, S.
- Abraham, B.
- Antoniotti, A.
- Armero, R.
- Audhuy, B.
- Aumaitre, H.
- Beaucaire, G.
- Beck-Wirth, G.
- Berger, J.L.
- Bernard, L.
- Beuscart, C.
- Bodard, L.
- Bouchaud, O.
- Boue, F.
- Cabane, J.-P.
- Cabié, A.
- Champagne, H.
- Cheneau, C.
- Chennebault, J.-M.
- Cheret, A.
- Christian, B.
- Compagnucci, A.
- Daneluzzi, V.
- Debab, Y.
- Dellamonica, P.
- Delfraissy, F.
- Devidas, A.
- Diab, G.
- Doll, J.
- Drobacheff-Thebaut, C.
- Durel, A.
- Esnault, L.
- Faba, L.
- Froguel, E.
- Garipuy, D.
- Garrait, V.
- Geffray, L.
- Genet, C.
- Genet, P.
- Gérard, L.
- Ghosn, J.
- Girard, J.
- Girard, Pascal
- Godin-Collet, C.
- Hochedez, P.
- Hoen, B.
- Houlbert, D.
- Jacomet, C.
- Jeantils, V.
- Jidar, K.
- Klement, E.
- Lafeuillade, A.
- Launay, V.
- Leprêtre, A.
- Levy, Y.
- Makhloufi, D.
- Malbec, D.
- Martha, B.
- May, T.
- Merrien, D.
- Miailhes, P.
- Miodovski, C.
- Morlat, P.
- Mortier, E.
- Neau, D.
- Obadia, M.
- Patey, O.
- Pellegrin, L.
- Perronne, V.
- Philibert, P.
- Pialoux, G.
- Pichancourt, G.
- Piroth, L.
- Poinsignon, Y.
- Poizot-Martin, I.
- Prazuck, T.
- Prendki, V.
- Du Clary, F.
- Quinsat, D.
- Regnier, A.
- Reynes, J.
- Rosenthal, E.
- Rouveix, E.
- Salmon, D.
- Salanville, F.
- Schmitt, L.
- Simon-Coutellier, A.
- Sotto, A.
- Souala, F.
- Stein, A.
- Timsit, F.
- de Truchis, P.
- Uludag, A.
- Vaillant, O.
- Verdon, R.
- Verlesch-Langlin, A.
- Viard, J.-P.
- Vittecoq, D.
- Weiss, L.
- Yéni, P.
- Zucman, D.
- Allavena, C.
- Allegre, T.
- Amri, I.
- Autran, B.
- Bacchus, C.
- Blanc, C.
- Bonne, S.
- Bonne, B.
- Bouchez, S.
- Charlier, C.
- Consigny, H.
- Duvivier, C.
- Fourn, E.
- Guiroy, F.
- Huleux, T.
- Katlama, C.
- Lascoux, C.
- Leplatois, A.
- Lyavanc, T.
- Molina, J.-M.
- Naqvi, A.
- Nembot, G.
- Quertainmont, Y.
- Raffi, F.
- Samri, A.
- Schneider, L.
- Seang, S.
- Seksik, B.
- Shoai-Tehrani, M.
- Slama, L.
- Valentin, A.
- Yazdanpanah, Y.
- Alloui, C.
- Amiel, C.
- André, P.
- André, E.
- Anies, G.
- Barin, F.
- Bellecave, P.
- Bettinger, D.
- Bouvier-Alias, M.
- Brun-Vézinet, F.
- Calmy, A.
- Calvez, V.
- Caveng, W.
- Chaillon, A.
- Chapalay, S.
- Charpentier, C.
- Costagliola, D.
- Cottalorda, J.
- Delamare, C.
- Delaugerre, C.
- Dina, J.
- Santos, G.
- Ferre, V.
- Flandre, P.
- Fleury, H.
- Fourati, S.
- Gaille, C.
- Giraudeau, G.
- Guigon, A.
- Haim-Boukobza, S.
- Lagier, E.
- Le Guillou-Guillemette, H.
- Henquell, C.
- Izopet, Jacques
- Lambert-Niclot, Lambert
- Leroux, M.
- Maillard, A.
- Malet, I.
- Marcelin, Marc
- Marque-Juillet, S.
- Masquelier, B.
- Mirand, A.
- Morand, P.
- Montes, B
- Mouna, L.
- Noel, C.
- Pallier, C.
- Peytavin, G.
- Pinson-Recordon, P.
- Poveda, J.
- Raymond, S.
- Reigadas, S.
- Roques, A.
- de Rougemont, A.
- Roussel, C.
- Schmitt, P.
- Schneider, V.
- Schvoerer, E.
- Signori-Schmuck, A.
- Soulié, C.
- Tamalet, C.
- Tardy, C.
- Trabaud, A.
- Vabret, A.
- Vallet, S.
- Yerly, S.
DOIAbstract
International audienceBackground: Our study describes the prevalence of transmitted drug resistance (TDR) among 1318 French patients diagnosed at the time of primary HIV-1 infection (PHI) in 2007-12.Methods: HIV-1 resistance-associated mutations (RAMs) were characterized using both the 2009 WHO list of mutations and the French ANRS algorithm. A genotypic susceptibility score was estimated for each first-line recommended ART combination.Results: Patients were mainly MSM (72.6%). Non-B variants were identified in 33.7% of patients. The proportion of TDR was estimated as 11.7% (95% CI 10.0-13.5). The prevalences of PI-, NRTI-, first-generation NNRTI and etravirine/rilpivirine-associated RAMs were 2.5%, 5.2%, 3.9% and 3.2%, respectively. Single...
Add to ORKG